Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial

Authors: Justin Taylor, Xiaoli Mi, Alexander V Penson, Stella V Paffenholz, Kelsey Alvarez, Allison Sigler, Stephen S Chung, Raajit K Rampal, Jae H Park, Eytan M Stein, Martin S Tallman, Filiz Sen, Mithat Gönen, Omar Abdel-Wahab, Virginia M Klimek

Published: 2020-07-28

DOI: 10.1016/s2352-3026(20)30209-x

Source: Full article

---

Abstract

No abstract found.